Stroke Prevention in AF
.
Search
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Boehringer Ingelheim today reported a strong performance in 2022
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Boehringer Ingelheim inaugurates new milestone on its long-term commitment to the Kingdom
Generalized pustular psoriasis at EADV
Dr. Emmanuelle Clerisme-Beaty reflects on the latest developments for generalized pustular psoriasis at this year’s virtual EADV congress
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Women in STEM 2022
Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Metacam®
For the treatment of mastitis in lactating cows and for the control of pain associated with dehorning or surgery.
Drug Discovery at Boehringer Ingelheim
Find out more about the drug discovery process at Boehringer Ingelheim
Our Contribution
Humanity is facing serious challenges. We believe we can always do more – for ourselves and for the generations to come.
Vetmedin®
Treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid regurgitation).
“LastMile” – improving through digital
“LastMile” – improving through digital
Winners of 2020 BVDzero Case Awards announced
Winners of 2020 BVDzero Case Awards announced
Our Commitment
We want to create value in areas of unmet medical need and engage with communities and society to improve lives – for humans and animals.
Our Commitment to Stop Rabies
Through our Stop Rabies program, we are committed to education, vaccination, and surveillance, working alongside local governments, health authorities, veterinarians, and communities to eliminate Rabies.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Is artificial intelligence the future of farming?
Boehringer Ingelheim donates 75,000 doses of rabies vaccine
This significant rabies vaccine donation will support GARC’s efforts to address deaths due to rabies in Madagascar.
Mexico rabies free dog vaccination campaigns
Mexico: a champion in the fight against rabies. The first country in the world to be declared free from dog-transmitted rabies.
COVID-19 Protecting Our Employees
Meet BIs Brains Michael Sand
Dr. Michael Sand, Senior Clinical Program Leader, CNS at Boehringer Ingelheim shares his view on the complexities of the CNS research landscape.
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Leading experts shed light on importance of establishing dedicated stroke management centers
Leading experts shed light on importance of establishing dedicated stroke management centers across healthcare facilities
COVID-19: Research Update
Boehringer Ingelheim stops treatment with experimental medication in study investigating benefits for severely ill patients with COVID-19